Zanprol Tablets 10mg

Zanprol 10mg Tablets are an advanced treatment for the relief of heartburn and acid reflux. Note: We are only able to ship one box at a time of this product. Multiple orders will not be accepted.
Zanprol tablets contain the active ingredient omeprazole, which is a type of medicine called a proton pump inhibitor. Omeprazole acts in the stomach to decrease the production of stomach acid. Proton pumps are found on cells that line the stomach are used by these cells to produce stomach acid. Omeprazole works by inhibiting the action of the proton pumps, and this reduces the production of stomach acid. Acid is produced in the stomach as part of the normal digestive process. However, sometimes this acid can flow back into the oesophagus. This is called reflux, and can cause pain and heartburn. Omeprazole reduces the production of stomach acid and therefore stops excess acid flowing back into the foodpipe. It can be bought without a prescription from pharmacies to relieve heartburn symptoms associated with acid reflux. We are only able to provide one box at a time of this product. Multiples orders will not be accepted.
Directions
How To Take Zanprol: The tablets should be swallowed whole with plenty of liquid (e.g., water or fruit juice) prior to a meal. It is important that the tablets should not be crushed or chewed. Initially the dosage is 20mg once daily. Subsequently, symptomatic relief from heartburn can be achieved in some subjects by taking 10mg once daily, increasing to 20mg if symptoms return. The lowest effective dose should always be used. If no relief is obtained within two weeks then the patient should be referred to their doctor. If continuous treatment for more than 4 weeks is required to relieve symptoms then the patient should be referred to their doctor
Warnings
You should carefully read all product packaging and labels prior to use
Ingredients
Zanprol Contains: Omeprazole 10 mg
Side Effects
Omeprazole is well tolerated and adverse reactions have generally been mild and reversible. The following have been reported as adverse events in clinical trials or reported from routine use but in many cases a relationship to treatment with omeprazole has not been established. Skin and subcutaneous tissue disorders Skin rash, urticaria and pruritus have been reported, usually resolving after discontinuation of treatment. In addition photosensitivity, bullous eruption, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, alopecia and increased sweating have been reported in isolated cases. Musculoskeletal disorders Arthritic and myalgic symptoms have been reported and have usually resolved when therapy is stopped. Respiratory disorders In isolated cases bronchospasm has been reported. Gastrointestinal disorders Diarrhoea has been reported and may be severe enough to require discontinuation of therapy. Constipation, abdominal pain, nausea/vomiting and flatulence have been reported. In isolated cases dry mouth, stomatitis and candidiasis have been reported. Hepato-biliary disorders Increases in liver enzyme levels have been observed. In isolated cases, encephalopathy in patients with pre-existing severe liver disease, hepatitis with or without jaundice and rarely hepatic failure. Renal & urinary disorders Interstitial nephritis which has resulted in acute renal failure has been reported in isolated cases. Reproductive disorders In isolated cases gynaecomastia and impotence have been reported. Nervous system disorders Headache has been reported which may be severe enough to require discontinuation of therapy. Rarely paraesthesia has also been reported. Taste disturbances have been reported in isolated cases. Psychiatric disorders In isolated cases reversible mental confusion, agitiation, depression and hallucinations occurring predominantly in severely ill patients. Agression has also been reported in isolated cases. Disorders of the eye In isolated cases blurred vision has been reported. Haematological In isolated cases leucopenia, thrombocytopenia, agranulocytosis, hyponatraemia and pancytopenia have been reported. Disorders of the ear Vertigo has been reported. Disorders of the immune system Anaphylactic shock and angioedema have been reported in isolated cases. General disorders Dizziness, light-headedness and feeling faint have been associated with treatment, but all usually resolve on cessation of therapy. Somnolence and insomnia have also been reported. In isolated cases peripheral oedema, malaise and fever have been reported. In rare cases, drowsiness has been reported. If affected patients should not drive or operate machinery.
Size: 14